A seven-day course of antibiotics for hospitalized patients with bloodstream infections is just as effective as a 14-day course, according to new findings presented at #IDWeek2024. Learn more:

🚨 2️⃣ PhD opportunities with us in Melbourne @CAAR_Aus @TheDohertyInst 👇 1️⃣ PhD examining RCT validation of clinical decision rules in antibiotic allergy - beyond #PENFAST 2️⃣ PhD examining prolonged oral challenge in #penicillinallergy - #PROSPECTOR2 study Suited to

🦠We call a lot of things “sepsis” 🚨In our new @AnnalsofIM study, we examine how broad this grab bag really is ⚠️Among ~75,000 patients with sepsis, we found a remarkably wide spectrum of presentations & outcomes across infection source & organ dysfunction patterns Thread ⬇️

Great to see Trial Forge Guidance 4 on reporting guidance for SWATs and the EQUATOR network site ( https://t.co/7rXE8f53KP). Have a look at the SWAT reporting guidance is at: https://t.co/AsjB3YJEu2

🆕️⚡️⚡️Single-centre study Staphylococcus aureus bloodstream infection rates were 56% lower during the monsoonal wet season when patients on hemodialysis receive supervised melioidosis prophylaxis with trimethoprim sulfamethoxazole #idxposts

“In this cohort study of 8807 patients, we describe risk factors and clinical outcomes of patients with persistent Gram-negative bacteraemia” Read the #OpenAccess article by @seanongwx @syctong @BRxAD et al: https://t.co/JkWrmaujdh @OUPMedicine @OxfordJournals #JACNews

7/ Given the signal towards worse outcomes with more prolonged persistence, whether variable antibiotic durations (similar to SAB) or other adjunctive interventions can be used to improve outcomes is also an interesting question that merits further research.

6/ Overall, persistent bacteremia is uncommon but is a/w significantly worse outcomes in GN-BSI. Risk stratification tools may be helpful to identify these patients. Some of these have been developed but none has been well-validated in external cohorts to be recommended broadly.

5/ Enterobacterales BSI generally was a/w less persistence compared to non-Enterobacterales. But even among the Enterobacterales, there are differences, with Serratia having the highest odds and prevalence of PB - an association which has been previously described.

4/ This graph summarizes the prevalence of persistent bacteremia, which varied widely depending on causative organism. Y-axis shows crude prevalence and color (🔴 = higher/worse, 🟢 = lower/better) shows adjusted aOR of persistence for that organism compared to all other GN-BSI.

3/ Persistent bacteremia was a/w ⬆️ 30-day, 90-day mortality, and LOS, even after adjustment for potential confounders. aOR for mortality was higher amongst patients who had FUBC collected on day 4/5, hinting at a relationship with duration of bacteremia similar to SAB.

2/ Of 8807 patients with FUBC collected between D2-D5 of their GN-BSI, 600 (6.8%) had persistent bacteremia (PB) with the same index organism. Factors a/w ⬆️ odds of PB included permanent catheter use, AMR, nosocomial infx, ICU adm, resp/SSTI infx, and non-Enterobacterales infx..

Our new paper in @BSACandJAC : a follow-up paper to our previous FUBC study ( https://t.co/h6DHrmUlqw), further describing the risk factors and outcomes of patients with persistent GN-BSI. 1/ @syctong @DrKevinSchwartz @KevinAnBrown @BRxAD #IDtwitter https://t.co/5FnB9TRdOF

Preventing new Gram-negative resistance through beta-lactam de-escalation in hospitalized patients with sepsis: A retrospective cohort study ✅ Just Accepted 🔗

Whether antibiotic de-escalation reduces risk of subsequent antibiotic resistance is uncertain🆕️⚡️The largest study to date BL Abx De-escalation was associated w 🔽 risk of new GN resistance development compared to no change in hospitalized pts w Sepsis

Just out #AACJournal @ASMicrobiology. HCO3 Resensitisation of MRSA to B-lactam and outcomes in the CAMERA2 trial https://t.co/fx1pmsgvII First author: Neta Petersiel In memorandam of Arnold Bayer @Josh_S_Davis @BenjaminHowden @UniMelbMDHS @TheDohertyInst @stefanoinoz Thread

It is crucial for trials to be as relevant as possible to the populations they seek to inform, yet often trials lack diversity and fail to include a range of underserved groups. The #INCLUDE initiative is useful to help trials to address this 1/8 #MethodologyMonday #90

Association between infectious diseases consultation and mortality in hospitalized patients with Gram-negative bloodstream infection: a retrospective population-wide cohort study ✅ Just Accepted https://t.co/eQwopSHQXv

12/ And of course, we should advocate for increased access to ID consult services in all settings, especially in rural/community/underserved settings. And use this data to convince policymakers to train more ID specialists and incentivize choosing ID as a specialty 😀

11/ Does this mean EVERY patient with GN-BSI should be seen by ID? Probably difficult given the volume and how busy we already are. But certainly this shows we make a difference, and that any patient with any of the above high-risk features should receive an ID consult!